Investor’s Alert – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Biogen Idec Inc. (NASDAQ:BIIB).
New York, NY – (Net PR News) – 04/18/2013–smartOTCis the premiere destination for Investors and novices alike who wish to receive information on fast moving OTC stocks and undiscovered companies. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.
Sign up For Our No. 1 Rated Stock Newsletter to make Huge Profitshttp://www.smartotc.com
Trend analysis report of stocks at the Healthcare sector, Biotechnology industry. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) remained a higher volume stock in its industry and showing bearish movement during last trade and Biogen Idec Inc. (NASDAQ:BIIB) remained in the news while last trading due to their latest news and sizzling activities.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has scheduled to report its financial results, first quarter 2013, after closing the financial markets, on Tuesday, April 30, 2013. VRTX will also host, on that day, at 5:00 p.m. ET, a conference call.
Why Should Investors Buy VRTX After the Recent Fall? Just Go Here and Find Out
Healthcare sector stock, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the previous trading session the stock showed a negative movement of -0.63%. Currently, the company has a market capitalization of $11.79 billion. Stock’s closing price was $54.04, while it started its day-trade at $54.06. Its 52-week price range was $35.40 – $66.10.
VRTX traded with volume of 1.35 million shares, while its average trading remained 1.65 million shares. If we look at the previous 5 day’s performance of the stock, it remained optimistic with the jump of 1.52%. In its last one month’s trade it climbed 3.31%.
Biogen Idec Inc. (NASDAQ:BIIB) revealed that it has planned to release its financial results, prior to opening the financial markets, on Thursday, April 25, 2013, for the first quarter of 2013. After that, BIIB will host, at 8:00 a.m. ET, a live webcast where the management of the company will discuss the financial results.
Why Should Investors Buy BIIB After The Recent Gain? Just Go Here and Find Out
Biotechnology company moving upward during the previous trading session, Biogen Idec Inc. (NASDAQ:BIIB) traded with a climb of 0.97% and closed at $204.08 after gaining total volume of 1.31 million shares. Its opening price was $200.11. Its 52-week price range was $124.88 – $209.00.
Biogen Idec’s earnings per share is $5.76, while its beta value stands at 0.88 times. If we look at the previous 5 day’s performance of the stock, it remained optimistic with the gain of 5.57%. In its last one month’s trade it advanced 15.44%. BIIB has total market capitalization of $48.28 billion.
smartOTC is the premiere destination for Investors and novice alike who wish to receive information on fast moving OTC penny stocks and undiscovered companies. We are a marketing firm that releases paid reports on undiscovered companies looking to tell their stories. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.
While penny stocks pose a much more significant risk factor compared to large cap stocks, their lure of quick gains makes it a trading choice for many small time and beginner investors. There is nothing wrong with investments into penny stocks, the best advice is to do your own research and consult with your own financial professional. smartOTC reports and alerts should only be used as a starting point for your own due diligence.
PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.
Smartotc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The disclaimer is to be read and fully understood before using our site, or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Read Our Full Disclaimer at http://www.smartotc.com/disclaimer